Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
暂无分享，去创建一个
[1] A. Insa,et al. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients , 2017, Clinical lung cancer.
[2] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[3] K. Yoshida,et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study. , 2015, Translational lung cancer research.
[4] B. Chan,et al. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. , 2015, Translational lung cancer research.
[5] Yan Liu,et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation , 2015, Journal of Translational Medicine.